dupixent 300 mg

Dupixent is a biologic medication that contains the active substance Dupilumab. It is a fully human monoclonal antibody. The solution is sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow. It is supplied in a single-dose pre-filled syringe with a needle shield or a pre-filled pen.

2. Mechanism of Action:
Dupixent works by inhibiting the signaling of two key proteins involved in the inflammatory process: interleukin-4 (IL-4) and interleukin-13 (IL-13). By binding specifically to the IL-4 receptor alpha subunit, Dupixent blocks the activity of both IL-4 and IL-13, which are major drivers of the type 2 inflammation seen in conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

3. Therapeutic Indications (Uses):
Dupixent is used to treat several inflammatory conditions in adults and children. Common indications include:

• Atopic Dermatitis (Eczema): For the treatment of moderate-to-severe atopic dermatitis in adults and children (ages 6 months and older) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.

• Asthma: As an add-on maintenance treatment for moderate-to-severe asthma in adults and children (ages 6 years and older) with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): As an add-on treatment for adults with inadequately controlled CRSwNP.

• Eosinophilic Esophagitis (EoE): For the treatment of eosinophilic esophagitis in adults and children (ages 1 year and older) weighing at least 15 kg.

• Prurigo Nodularis: For the treatment of prurigo nodularis in adults.

4. Warnings and Precautions:
Dupixent can cause serious side effects. Close monitoring by your healthcare team is essential.

• Hypersensitivity Reactions (Allergic Reactions): Serious allergic reactions, including anaphylaxis and serum sickness, have been reported. Symptoms may include rash, itching, hives, difficulty breathing or swallowing, swelling of the face, lips, tongue, or throat, and fainting. If these occur, treatment should be discontinued immediately.

• Conjunctivitis and Keratitis: Eye problems such as conjunctivitis (pink eye), dry eye, and keratitis (inflammation of the cornea) have been reported. Patients should report new or worsening eye symptoms to their doctor.

• Eosinophilic Conditions: In rare cases, patients may develop vasculitis (inflammation of blood vessels) consistent with eosinophilic granulomatosis with polyangiitis (EGPA) or other eosinophilic conditions. Symptoms may include rash, worsening lung symptoms, and nerve problems.

• Parasitic (Helminth) Infections: Dupixent may weaken the immune response to parasitic infections. Pre-existing parasitic infections should be treated before starting Dupixent. If a patient becomes infected while on treatment and does not respond to anti-parasitic therapy, Dupixent should be temporarily stopped.

• Risk of Infections: Dupixent may increase the risk of infections, including herpes simplex virus infections (cold sores) and herpes zoster (shingles). Patients with a weakened immune system should be cautious.

• Vaccinations: Live vaccines should not be given to patients taking Dupixent. It is recommended that patients be up to date with all vaccinations, including live vaccines, before starting treatment. Non-live vaccines can be administered.

• Asthma-Related Events: Do not discontinue or change asthma medications without talking to your doctor. Dupixent is not used to treat acute asthma attacks.

• Pregnancy and Breastfeeding: There is limited data on the use of Dupixent in pregnant women. It should only be used if clearly needed. It is unknown if Dupixent passes into breast milk, so a decision should be made whether to discontinue breastfeeding or the drug.

5. Dosage and Administration:

• The dose and frequency depend on the condition being treated, the patient’s age, and weight. For many adult indications, the recommended dose is 300 mg injected subcutaneously every two weeks.

• Dupixent is administered by subcutaneous injection (into the fatty tissue under the skin), usually in the thigh or abdomen. It can be self-injected after proper training by a healthcare professional.

• The pre-filled syringe and pen are for single use only.

• If a dose is missed, administer it as soon as possible, then resume dosing on the regular schedule.

6. Storage:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. If needed, Dupixent can be stored at room temperature (up to 25°C / 77°F) for a maximum of 14 days. Do not expose to heat or direct sunlight.